Amyris delivers high-performance alternatives to petroleum, plant and animal-based products across a wide range of consumer and industry segments. Our products offer customers a way to reduce environmental impact with No Compromise® in performance or availability. We are making better chemistry biologically.
EMERYVILLE, Calif., Oct. 05, 2017 (GLOBE NEWSWIRE) -- Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced that it has entered into a product development and production agreement for a new class of human nutrition ingredients with Koninklijke DSM N.V. (Royal DSM) (AEX:DSM.AS), the global science-based company active in health, nutrition and materials. With this latest agreement, Amyris and DSM have now executed several key partnership agreements focused on developing and producing solutions that serve large markets within the animal and human health and nutrition segments.
DSM is partnering with Amyris to fund development of the technology to produce critical ingredients on a cost-effective basis utilizing Amyris's capabilities coupled with DSM's sustainability-focused business model and brand recognition. DSM will commercialize innovative new human nutrition solutions incorporating these ingredients utilizing its robust global sales and marketing channel. The partnership announced today is focused on developing the ingredient for market introduction in 2019.
"Our partnership with DSM will allow us to introduce a new generation of ingredients targeted for human nutrition," said John Melo, President and CEO of Amyris. "With this development, we are working toward fulfilling our mission, providing consumers with sustainably-sourced, healthy and nutritious products. Our product and production platform will create a unique position and broadened access for a number of critical ingredients. DSM's market leadership in many areas, including in human health and nutrition, complements the broad technical capabilities Amyris has built to date. This collaboration includes a material initial payment and will result in significant medium term product revenue."
"Our collaboration with DSM, a leader in human health and nutrition, will result in an ability to deliver human nutrition solutions, resulting in improved human health and well-being," said Cindy Bryant, Senior Vice President and Head of Collaborations at Amyris.
Amyris is the integrated renewable products company that is enabling the world's leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules and produce specialty ingredients and consumer products. The company is delivering its No Compromise™ products across a number of markets, including specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, pharmaceuticals, and nutraceuticals. More information about the company is available at www.amyris.com.
This release contains forward-looking statements regarding Amyris, and any statements regarding Amyris other than statements of historical facts could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events (such as the expected production of a new class of human nutrition ingredients on a cost-effective basis, the anticipated timing for commercialization and market introduction of products incorporating such ingredients, the expected introduction of a new generation of ingredients targeted for human nutrition, the anticipated broadening of access for a number of critical ingredients using Amyris's product and production platform, expected medium term product revenue resulting from the collaboration with DSM, and the anticipated delivery of human nutrition solutions that result in improved human health and well-being) that involve risks and uncertainties. These statements are based on management's current expectations and actual results and future events may differ materially due to risks and uncertainties, including risks related to manufacturing capacity at Amyris's Brotas facility, delays or failures in development, production and commercialization of products, liquidity and ability to fund capital expenditures, Amyris's reliance on third parties to achieve its goals, and other risks detailed in the "Risk Factors" section of Amyris's quarterly report on Form 10-Q filed on August 14, 2017. Amyris disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.
Amyris, the Amyris logo and No Compromise are trademarks or registered trademarks of Amyris, Inc. All other trademarks are trademarks of their respective owners.